Investing Profile

Veronica Gambillara Fonck

InvestorVC
Partner at Pureos Bioventures
pureosbio.comZurich, Switzerland
Photo of Veronica Gambillara Fonck, Partner at Pureos Bioventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Eidgenössische Technische Hochschule Zürich Network
60 CONNECTIONS
ETH Zürich Network
48 CONNECTIONS
EPFL (École polytechnique fédérale de Lausanne) Network
29 CONNECTIONS
IMD Business School Network
28 CONNECTIONS
EPFL Network
25 CONNECTIONS
cb
$100K - $5.0M
$1.5M
4
$205M
CompanyStageDateRound SizeTotal Raised
AnaCardio
Series AJan 2025$18M
$18M
Memo Therapeutics
Series CNov 2023$28M
$75M
Co-investors: Philippe Dro (Adjuvant Capital), Hadrien Bouchez (Kurma Partners)
Minervax
Series UnknownOct 2023$57M
Series CDec 2022$23M
$140M
Co-investors: Kabeer Aziz (Adjuvant Capital), Christopher Gagliardi (Sanofi Ventures), Vincent Brichard (EQT Group)
Director Clinical and Regulatory Affairs Glycovaxyn AGPresent
Director Business Development Glycovaxyn AGPresent
Project Manager EndoArt SAPresent
Manager Clinical Affairs AllerganPresent
Executive Director, Clinical and Regulatory Affairs Glycovaxyn AGPresent
Chairperson of the Board Minervax ApSPresent
CEO-Co-founder LimmaTech Biologics AGPresent
CEO-and Co-Founder GlycoEra AGPresent
Partner Pureos BioventuresPresent
International Institute for Management Development Master of Business Administration - MBA Finance, General
ETH Zürich Engineer Material Engineer
Eidgenössische Technische Hochschule Zürich Engineer Material Engineer
EPFL (École polytechnique fédérale de Lausanne) PhD Biomedical Engineer
EPFL PhD Biomedical Engineer
Management BioTech, BioMed and Pharma Ventures Certificate of Advanced Studies Management BioTech, BioMed and Pharma Ventures
Advanced Course of Vaccinology CME credits Vaccine
IMD Master of Business Administration - MBA Finance, General
IMD Business School Master of Business Administration - MBA Finance, General
Sign in with Google →
Sign in with Google →